Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
Related Articles
Promising Results for Combined Therapy in Unresectable… : Oncology Times
An abstract is unavailable.
Ramucirumab/Somatostatin Displays Prolonged Survival in Advanced NET
A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.
Is SBRT Better Than Ablation for Small Liver Cancer?
SBRT showed superiority over radiofrequency ablation in local progression-free survival and tumor control in small HCC but similar overall survival and safety outcomes.
How I manage iron overload in the hematopoietic cell transplantation setting
It has long been recognized that iron overload is toxic and that diagnosis and management of iron overload in patients with hematological disorders are com
LSD1 and CoREST2 Potentiate STAT3 Activity to Promote Enteroendocrine Cell Differentiation in Mucinous Colorectal Cancer
STAT3 activity mediated by LSD1 and CoREST2 induces enteroendocrine cell specification in mucinous colorectal cancer, suggesting disrupting interaction among LSD1, CoREST2, and STAT3 as a…
Could fecal microbiota transplantation help patients heal after stem cell transplantation?
Fred Hutch news release clinical trial shows fecal microbiota transplantation helped with gut microbiome recovery in patients after stem cell transplantation
Tumour hypoxia in driving genomic instability and tumour evolution
Nature Reviews Cancer – In this Review, Suvac et al. discuss how intratumoural hypoxia is a driving force in tumour evolution, alongside driver gene mutations,…
Pevonedistat and Belinostat Therapy Demonstrates Safety, Modest Activity for Patients With R/R Acute Myeloid Leukemia or High-Risk MDS
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some…
Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer
The open-label, global, randomized phase III BREAKWATER study was an analysis of first-line encorafenib plus cetuximab plus chemotherapy in patients with BRAF V600E–mutant metastatic colorectal…
Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC
Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.